Degradation of Bronchodilator Agents in Oxymix System

1973 ◽  
Vol 62 (5) ◽  
pp. 823-825 ◽  
Author(s):  
George H. Kronberg ◽  
Bertil H. Takman
Keyword(s):  
Bronchodilator Agents

In vitro studies on the relative potency of bronchodilator agents

Lung ◽  
1985 ◽  
Vol 163 (1) ◽  
pp. 161-171 ◽  
Author(s):  
Joseph H. Fleisher ◽  
Jacob L. Pinnas
Keyword(s):  
In Vitro Studies ◽  
Relative Potency ◽  
Bronchodilator Agents

New isoquinolines as potential bronchodilator agents

Tetrahedron ◽  
1973 ◽  
Vol 29 (6) ◽  
pp. 857-862 ◽  
Author(s):  
S.F. Dyke ◽  
A.W.C. White ◽  
D. Hartley
Keyword(s):  
Bronchodilator Agents

scholarly journals Misuse of Inhaled Bronchodilator Agents

BMJ ◽  
1965 ◽  
Vol 1 (5441) ◽  
pp. 1037-1038 ◽  
Author(s):  
K. B. Saunders
Keyword(s):  
Bronchodilator Agents

scholarly journals Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment

2021 ◽  
Vol 10 (12) ◽  
pp. 2649
Author(s):  
Shih-Lung Cheng
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lung Function ◽  
Combination Therapy ◽  
Fixed Dose ◽  
Chronic Obstructive ◽  
Bronchodilator Agents ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Dose Combination ◽  
Long Acting

The effectiveness and safety of fixed dual long-acting bronchodilators for chronic obstructive pulmonary disease (COPD) patients have been well established; however, there is a paucity of clinical effectiveness comparison in patients with COPD treatment. The aim of the current study was to compare the effectiveness of three once-daily dual bronchodilator agents in patients with COPD. Patients with diagnosed COPD and treated with a long-acting beta-agonist (LABA) + long-acting muscarinic antagonist (LAMA) fixed-dose combination therapy (UME/VIL (umeclidinium and vilanterol inhalation powder), IND/GLY (indacaterol and glycopyrronium), and TIO/OLO (tiotropium and olodaterol)) were enrolled in this retrospective study over a period of 12 months. Effectiveness assessments were evaluated using a COPD assessment test (CAT) and lung function parameters. Besides, times for acute exacerbation were also assessed. The enrolled patients’ number was 177 in IND/GLY, 176 in UME/VIL and 183 in TIO/OLO. Lung function measurements with FEV1 had significantly improved for patients using TIO/OLO (98.7 mL) compared to those of IND/GLY (65.2 mL) and UME/VIL (64.4 mL) (p < 0.001). CAT scores were also significantly decreased in patients treated with TIO/OLO (CAT down 5.6) than those with IND/GLY (3.8) and UME/VIL (3.9) (p = 0.03). Acute exacerbation was also reduced in patients using TIO/OLO (4.9%) compared with those using IND/GLY (10.2%) and UME/VIL (11.9%) (p = 0.01). Significant improvement in pulmonary function, symptoms were demonstrated after 12 months of LABA/LAMA fixed-dose combination therapy with three different treatment options. TIO/OLO demonstrated higher therapeutic effects compared with UME/VIL or IND/GLY. Determining clinical relevance will require a well-designed randomized controlled trial.

Sign in / Sign up

Export Citation Format

Share Document